BiotechTube

Erenumab

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Episodic Migraine

Conditions

Episodic Migraine

Trial Timeline

Feb 8, 2018 → Jan 13, 2020

NCT ID
NCT03333109

About Erenumab

Erenumab is a phase 3 stage product being developed by Novartis for Episodic Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT03333109. Target conditions include Episodic Migraine.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT04084314ApprovedCompleted
NCT03867201Phase 3Completed
NCT03333109Phase 3Completed

Competing Products

19 competing products in Episodic Migraine

See all competitors
ProductCompanyStageHype Score
GalcanezumabEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 3
77
BOTOX + PlaceboAbbViePhase 3
77
Atogepant 60 mgAbbViePhase 3
77
Atogepant + UbrogepantAbbVieApproved
85
Atogepant + Placebo-Matching AtogepantAbbViePhase 3
77
SOM230 + PlaceboNovartisPhase 2
52
AMG334 + Oral ProphylacticNovartisApproved
85
AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS)NovartisPhase 3
77
Placebo + AMG 301AmgenPhase 2
51
Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride)PfizerPhase 1
32
Eptinezumab + PlaceboLundbeckPhase 3
74
Eptinezumab + PlaceboLundbeckPhase 3
74
Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type AIpsenPhase 3
74
IPN10200 + IPN10200 dose A + IPN10200 dose BIpsenPhase 2
49
DFN-11Dr. Reddy's LaboratoriesPhase 3
74
MethylprednisoloneBrain BiotechApproved
77

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85